US researchers have developed a new one-step procedure for introducing tritium radiolabels into pharmaceuticals in unique molecular positions by using an iron catalyst. The method not only provides a new diagnostic tool for ADMA (absorption, distribution, metabolism, excretion) studies, which are essential to assay the efficacy and safety of drug like compounds, but also minimises radioactive waste.